- Home
- MYN vs ESPR Comparison
MYN vs ESPR Comparison
Compare MYN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- ESPR
- Stock Information
- Founded
- MYN 1992
- ESPR 2008
- Country
- MYN United States
- ESPR United States
- Employees
- MYN N/A
- ESPR N/A
- Industry
- MYN Finance Companies
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- ESPR Health Care
- Exchange
- MYN Nasdaq
- ESPR Nasdaq
- Market Cap
- MYN 382.4M
- ESPR 305.0M
- IPO Year
- MYN N/A
- ESPR 2013
- Fundamental
- Price
- MYN $10.00
- ESPR $1.39
- Analyst Decision
- MYN
- ESPR Buy
- Analyst Count
- MYN 0
- ESPR 7
- Target Price
- MYN N/A
- ESPR $6.36
- AVG Volume (30 Days)
- MYN 86.0K
- ESPR 4.5M
- Earning Date
- MYN 01-01-0001
- ESPR 03-04-2025
- Dividend Yield
- MYN 4.12%
- ESPR N/A
- EPS Growth
- MYN N/A
- ESPR N/A
- EPS
- MYN N/A
- ESPR N/A
- Revenue
- MYN N/A
- ESPR $332,314,000.00
- Revenue This Year
- MYN N/A
- ESPR $5.51
- Revenue Next Year
- MYN N/A
- ESPR $1.42
- P/E Ratio
- MYN N/A
- ESPR N/A
- Revenue Growth
- MYN N/A
- ESPR 185.66
- 52 Week Low
- MYN $8.47
- ESPR $1.35
- 52 Week High
- MYN $10.62
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- MYN 47.13
- ESPR 33.54
- Support Level
- MYN $9.80
- ESPR $1.35
- Resistance Level
- MYN $10.17
- ESPR $1.75
- Average True Range (ATR)
- MYN 0.10
- ESPR 0.09
- MACD
- MYN 0.00
- ESPR -0.01
- Stochastic Oscillator
- MYN 52.70
- ESPR 10.00
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.